http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022280492-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443 |
| filingDate | 2020-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee60748faf280662c497e178e34fe92d |
| publicationDate | 2022-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022280492-A1 |
| titleOfInvention | Therapeutic agent for cancer having resistance to anti-ccr4 antibody |
| abstract | An object of the present invention is to provide a therapeutic agent having an excellent effect on ATL patients with a history of treatment with an anti-CCR4 antibody, in other words, ATL patients who developed resistance to an anti-CCR4 antibody. An EZH1/2 dual inhibitor, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof was found to have an excellent effect on anti-CCR4 antibody-resistant cancer (particularly mogamulizumab-resistant cancer). |
| priorityDate | 2019-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.